Vitamin E
1. Identity: Chemical Names, Natural Sources, and Common Forms
Naturally occurring vitamin E exists in eight chemical forms — alpha-, beta-, gamma-, and delta-tocopherol and alpha-, beta-, gamma-, and delta-tocotrienol — that have varying levels of biological activity. The name "tocopherol" was derived from the Greek words τοκος (birth) and φορειν (to bear or carry), meaning in sum "to carry a pregnancy," with the ending -ol signifying its status as a chemical alcohol. All forms feature a chromanol ring with a hydroxyl group that can donate a hydrogen atom to reduce free radicals and a hydrophobic side chain that allows penetration into biological membranes; both the tocopherols and tocotrienols occur in alpha, beta, gamma, and delta forms, determined by the number of methyl groups on the chromanol ring.
The structural difference between tocopherol and tocotrienol molecules involves the phytyl tail they share; tocotrienols have three double bonds in this tail while tocopherols do not. Alpha- (or α-) tocopherol is the only form recognized to meet human requirements. Serum concentrations of vitamin E (alpha-tocopherol) depend on the liver, which takes up the nutrient after the various forms are absorbed from the small intestine. Other naturally occurring forms of vitamin E — β-, γ-, δ-tocopherols and the tocotrienols — do not contribute toward meeting the vitamin E requirement because, although absorbed, they are not converted to α-tocopherol by humans and are recognized poorly by the α-tocopherol transfer protein in the liver.
Natural Food Sources
Vitamin E is present in several foods, including nuts, seeds, vegetable oils, and green leafy vegetables. The most common form of tocopherol in the North American diet is γ-tocopherol, the predominant form of vitamin E in corn oils, while the form with the highest biological activity and most common form in European diets is α-tocopherol, found in olive and sunflower oils. Tocotrienols are found in palm oil, barley, oats, and rice bran, and have higher antioxidant activity than tocopherols.
Common Supplement Forms and Preparations
Supplements of vitamin E typically provide only alpha-tocopherol, although mixed products containing other tocopherols and even tocotrienols are available. Naturally occurring alpha-tocopherol exists in one stereoisomeric form. In contrast, synthetically produced alpha-tocopherol (all-rac-alpha-tocopherol, commonly labeled as DL or dl) contains equal amounts of its eight possible stereoisomers, and serum and tissues maintain only four of these stereoisomers. A given amount of synthetic alpha-tocopherol is therefore only half as active as the same amount (by weight in mg) of the natural form (RRR-alpha-tocopherol, commonly labeled as D or d).
Alpha-tocopherol in dietary supplements and fortified foods is often esterified to prolong its shelf life while protecting its antioxidant properties. Vitamin E in dietary supplements and fortified foods is often an esterified form of α-tocopherol, the most common esters being acetate and succinate; these esters are hydrolyzed and converted into free α-tocopherol prior to absorption in the intestinal tract. Alpha-tocopherol, either naturally extracted from plant oils or, most commonly, as the synthetic tocopheryl acetate, is sold as a popular dietary supplement, either by itself or incorporated into a multivitamin product, and in oils or lotions for use on skin.
2. History and Discovery
Vitamin E was first discovered in 1922 by Evans and Bishop as "a hitherto unrecognized dietary factor necessary for reproduction." Specifically, female rats raised on a diet of pure fat, carbohydrate, protein, salt, vitamins A and B were healthy in all apparent aspects, but they could not carry a pregnancy to term because they always reabsorbed the fetus. Fertility was restored by supplementing the diet with certain foods such as lettuce, and thus it was determined that a certain "anti-sterility vitamine" was present in these foods.
The substance was subsequently named by Sure in 1924, and the antioxidant function of vitamin E was identified by Cummings and Mattill in 1931. The chemical structure of vitamin E was elucidated by the German chemist Erhard Fernholz in 1938 while working in the United States. Shortly after Fernholz's proposal, the Swiss chemist Paul Karrer achieved the chemical synthesis of α-tocopherol for the first time; Karrer condensed trimethyl hydroquinone with phytol bromide derived from natural phytol, using zinc chloride as a catalyst. The molecule (alpha-tocopherol) was isolated in 1935, synthesized in 1938, and manufactured by Hoffmann La Roche shortly thereafter.
Vitamin E was first reported to have therapeutic effects in patients with cardiovascular disease by Vogelsang and Shute in 1946. Subsequent research has shed light on vitamin E's influence on enzyme activities, signaling cascades, gene expression, and bio-membrane structure, though the overall understanding of the vitamin's mechanism of action still remains fragmentary.
Traditional and Historical Use
The modern scientific history of vitamin E, as a nutrient identified through laboratory research in the early 20th century, differs markedly from most botanical supplements, which have long histories of folk or ethnomedicinal use. Vitamin E does not have a pre-scientific record of intentional medicinal application under the name "vitamin E." The reproductive factor that would later be identified as vitamin E was abundantly found in lettuce, butterfat, and vegetable oils — foods long incorporated into traditional diets across many cultures. Initially, animal studies focused on reproductive health and growth disorders, but later research highlighted vitamin E's role in preventing encephalomalacia in domestic fowl and muscular dystrophy in various animals. The therapeutic exploration of vitamin E in humans is thus essentially a product of 20th-century biomedical research rather than traditional medicine systems.
3. Key Constituents and Mechanisms of Action
Primary Antioxidant Mechanism
The antioxidant property of vitamin E is exerted through the phenolic hydroxyl group, which readily donates its hydrogen to the peroxyl radical, resulting in the formation of a stable lipid species. In donating the hydrogen atom, vitamin E becomes a relatively unreactive free radical as the unpaired electron becomes delocalised into the aromatic ring. Vitamin E is able to scavenge peroxyl radicals, essentially neutralizing them to form hydroperoxides. Lipid peroxyl radicals are formed during lipid peroxidation: following an initiating event induced by a reactive oxygen species, a hydrogen molecule is abstracted from a C–H bond weakened by its proximity to an electron-withdrawing double bond found in polyunsaturated fatty acids (PUFAs), forming a carbon-centred radical. During this process there is molecular rearrangement of the lipid to a conjugated diene structure and addition of O₂ to the carbon-centred radical, giving rise to a lipid peroxyl radical. This radical is highly reactive and, if not quenched, will react with a nearby PUFA, propagating lipid peroxidation. As a scavenger of peroxyl radicals, vitamin E acts to inhibit this chain reaction and is therefore termed a chain-breaking lipid antioxidant.
When vitamin E scavenges peroxyl radicals, it is converted into a vitamin E radical, which may be further oxidized into α-tocopherylquinone or reduced by vitamin C or other reducing compounds to regenerate vitamin E. α-Tocopherylquinone is a biomarker of the antioxidant action of vitamin E.
Non-Antioxidant Mechanisms
Vitamin E can exert its action through both redox-dependent and independent mechanisms, modulating enzymes and receptors involved in signal transduction and gene expression pathways and affecting the action of different transcription factors. The modulation of signal transduction pathways also appears to be mediated in a non-antioxidant manner. The main function of α-tocopherol is recognized as its antioxidant effect preventing lipid peroxidation of polyunsaturated fatty acids in the cell membrane, but many other functions — such as activation of signal transduction and gene expression that are not related to the antioxidant effect — have been reported.
Studies have shown that vitamin E has the biochemical activity to modulate signaling pathways (such as Nrf2), inflammatory molecules, apoptotic regulators, cytokines, kinases (e.g., MAPK), and antioxidant enzymes. The efficiency of antioxidant protection depends on two factors: firstly, the mobility of the molecule in membranes, which is determined by the aliphatic tail; secondly, the number of methyl species on the chromanol ring, with each methyl group conferring additional antioxidant capacity. In addition, the proximity of the methyl species to the hydroxyl group is an important factor. Therefore α-homologues, which have the greatest number of methyl species and in which these flank the hydroxyl group, are thought to be more effective than the other homologues.
The α-tocopherol transport protein (TTP) is responsible for carrying α-tocopherol to vital organs. It has a poorer efficiency transporting tocotrienols to tissues, and the lack of relative specific affinity of TTP for tocotrienols led to the notion that availability of dietary tocotrienol to vital organs may be limited.
4. Scientific Evidence by Area of Use
4.1 Cardiovascular Disease
Early observational and mechanistic evidence suggested that vitamin E might protect against cardiovascular disease (CVD) by reducing lipid peroxidation and LDL oxidation. Studies following supplementation in humans clearly showed that α-tocopherol decreases lipid peroxidation, platelet aggregation, and functions as a potent anti-inflammatory agent. However, prospective human clinical trials with α-tocopherol alone and in combination with other antioxidants have been largely negative.
In the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) study, 29,133 male smokers in southwestern Finland were assigned to receive 50 mg/day of vitamin E (all-rac-α-tocopherol acetate) or placebo in a 2×2 design, with a median treatment of 6.1 years; no significant reduction was noted in nonfatal myocardial infarction or coronary heart disease (CHD) mortality.
The HOPE Study reported no apparent effect of vitamin E supplementation on cardiovascular outcomes in high-risk patients; this study consisted of 2,545 women and 6,996 men aged 55 years or older who had documented vascular disease or diabetes plus one other coronary risk factor. The HOPE study failed to demonstrate any clinical benefit on cardiovascular outcomes with the daily administration of 400 IU vitamin E for 4.5 years.
The GISSI trial, conducted in Italy among 11,324 patients within three months of a myocardial infarction (MI), investigated whether all-rac-alpha-tocopherol at 300 mg/day (330 IU/day) over 3.5 years had an effect on the primary combined endpoint of death, MI, and stroke.
In the five large clinical trials (ATBC, CHAOS, GISSI, HOPE, PPP), the total number of cardiovascular events reported in the vitamin E group was 2,098 versus 2,140 in the placebo group for a relative risk of 0.98, suggesting that the benefit of vitamin E supplementation was small or absent. Three large randomized clinical trials (GISSI, HOPE, and the Primary Prevention Project) with a combined total of more than 25,000 patients failed to show a significant benefit with vitamin E taken as a dietary supplement for the prevention of CHD.
Evidence strength: The available scientific studies offer little evidence that supplementation with vitamin E has any benefit on cardiovascular disease prevention or treatment. Evidence from multiple large, well-powered RCTs is consistently null for hard cardiovascular endpoints.
4.2 Cancer
Antioxidant nutrients like vitamin E protect cell constituents from the damaging effects of free radicals that, if unchecked, might contribute to cancer development. Despite this biological rationale, large intervention trials have not confirmed a protective effect and, in one key trial, supplementation was associated with harm.
Over 35,000 men aged 50 and older participated in the Selenium and Vitamin E Cancer Prevention Trial (SELECT). The trial was initially planned for a minimum of seven years to a maximum of 12 years of supplementation. The independent Data and Safety Monitoring Committee met in September 2008 and found that selenium and vitamin E, taken alone or together, did not prevent prostate cancer. The additional follow-up data showed that the men who took vitamin E alone had a 17 percent relative increase in numbers of prostate cancers compared to men on placebo, and this difference was statistically significant and not likely to be due to chance.
This randomized, double-blind, placebo-controlled, 2×2 factorial design clinical trial found that neither selenium nor vitamin E reduced the incidence of prostate cancer after seven years and that vitamin E was associated with a 17% increased risk of prostate cancer compared to placebo.
Evidence strength: No benefit for cancer prevention has been established from supplemental vitamin E in clinical trials. The SELECT trial produced evidence of potential harm (increased prostate cancer risk) in healthy men receiving high-dose supplementation.
4.3 Non-Alcoholic Fatty Liver Disease (NAFLD/NASH)
Non-alcoholic fatty liver disease (NAFLD), now also recognized as metabolic dysfunction-associated steatotic liver disease (MASLD), is a common chronic liver condition characterized by hepatic steatosis and inflammation, with an increased risk of developing fibrosis and cirrhosis. One of the leading causes of the beginning and progression of NAFLD is oxidative stress.
A systematic review of eight RCTs conducted between 2010 and January 2020 showed that vitamin E has clinical utility in improving biochemical (ALT and AST levels) and histological abnormalities in NAFLD, including hepatic steatosis and lobular inflammation. However, vitamin E does not seem to have significant effects on liver fibrosis.
A separate systematic review of 11 studies indicated that vitamin E supplementation significantly reduces serum aminotransferases and improves histological parameters such as steatosis and inflammation. However, the evidence regarding its efficacy in enhancing fibrosis remains inconclusive, highlighting a significant gap in the current literature.
Evidence strength: Moderate. Multiple RCTs and systematic reviews support improvements in liver enzymes and histological markers of steatosis and lobular inflammation. The effect on hepatic fibrosis remains uncertain. Long-term safety in this population requires further investigation.
4.4 Alzheimer's Disease and Cognitive Decline
Vitamin E has several biological activities, including functioning as an antioxidant to scavenge toxic free radicals. Evidence that free radicals may contribute to the pathological processes behind cognitive decline supports its investigation in Alzheimer's disease (AD).
A Cochrane systematic review found that four trials met the inclusion criteria for vitamin E in AD and mild cognitive impairment (MCI), but outcomes could only be extracted from two trials: one in an AD population (n=304) and one in an MCI population (n=516). Both trials had an overall low to unclear risk of bias. It was not possible to pool data across studies owing to a lack of comparable outcome measures.
In people with AD, the Cochrane review found no evidence of any clinically important effect of vitamin E on cognition, measured with change from baseline in the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog) over six to 48 months (mean difference −1.81, 95% CI −3.75 to 0.13, P=0.07; 1 study, n=272; moderate quality evidence).
Evidence strength: Weak. The available RCT evidence, assessed by Cochrane methodology, shows no clinically important benefit for cognition in AD. Evidence for prevention of progression in MCI is equally limited. Data quality and comparability between trials remain significant constraints.
4.5 Age-Related Macular Degeneration (AMD)
The eye is particularly susceptible to oxidative stress, and disruption of the delicate balance between oxygen-derived free radicals and antioxidants can lead to many degenerative diseases. Vitamin E has been investigated as part of multi-nutrient antioxidant regimens for AMD.
The original Age-Related Eye Disease Study (AREDS), launched in 1996, showed that a dietary supplement formulation containing 500 mg vitamin C, 400 IU vitamin E, 2 mg copper, and 80 mg zinc reduced the risk of progression to advanced AMD. The AREDS was an 11-center double-masked clinical trial that enrolled participants who had extensive small drusen, intermediate drusen, large drusen, noncentral geographic atrophy, or pigment abnormalities in one or both eyes, or advanced AMD or vision loss due to AMD in one eye.
In the clinical setting, population-based studies on vitamin E supplementation for AMD have been inconsistent at times and follow-up studies are needed. The therapeutic role of vitamin E in retinal disease pathogenesis has been widely explored, with a focus on limiting the progression of retinal disease with vitamin E treatment, especially dry AMD.
Evidence strength: Moderate, but primarily for the combination antioxidant formulation (AREDS), not for vitamin E alone. The contribution of vitamin E independently to AMD risk reduction within the multi-ingredient AREDS formula cannot be established from the trial design.
4.6 Immune Function
Vitamin E is an antioxidant that plays an important role in immune function by helping maintain cell membrane integrity and epithelial barriers and by enhancing antibody production, lymphocyte proliferation, and natural killer cell activity. Vitamin E also limits inflammation by inhibiting the production of proinflammatory cytokines.
Human and animal studies suggest that vitamin E deficiency impairs humoral and cell-mediated immunity, is associated with reduced natural killer cell activity, and increases susceptibility to infection. It is not clear whether vitamin E supplements reduce the risk or severity of respiratory infections; some studies have found that vitamin E supplements might help, but others have not, and the effects might depend on whether someone has low vitamin E levels.
Evidence strength: Moderate for the role of adequate vitamin E status in immune function; preliminary and mixed for the effect of supplementation beyond adequacy on immune outcomes in generally healthy populations.
4.7 Neurological Health
Vitamin E deficiency was reported to cause cellular atrophy and a reduction of dendritic branching of Purkinje neurons together with cognitive deficits, while vitamin E supplementation prevented these defects. Vitamin E deficits are associated with impaired motor coordination, cognitive functions, ataxia, and lipid peroxidation. Moreover, vitamin E deficiency may cause an impairment of the blood–brain barrier through the increase of brain oxidative stress.
Overt vitamin E deficiency is very rare, seen only in individuals unable to absorb the vitamin or with inherited abnormalities that prevent the maintenance of normal blood concentrations. Current dietary patterns appear to provide sufficient vitamin E to prevent deficiency symptoms such as peripheral neuropathy.
Evidence strength: Well-established for deficiency-related neurological symptoms (peripheral neuropathy, ataxia). Evidence for supplementation improving neurological outcomes beyond correcting deficiency is limited in humans.
5. Dosage Forms and Doses Reported in Studies
The RDA for vitamin E (natural form) in adults is 15 mg (22.4 IU). The RDA for vitamin E is 4 to 15 mg for infants and children depending on age, and 15 to 19 mg for adults, including women who are pregnant or lactating.
- ATBC Study: 29,133 male smokers received 50 mg/day of vitamin E (all-rac-α-tocopherol acetate) for a median of 6.1 years.
- HOPE Study: 400 IU of vitamin E daily for 4.5 years.
- GISSI Trial: All-rac-alpha-tocopherol at 300 mg/day (330 IU/day) over 3.5 years.
- PPP Study: 300 mg/day of vitamin E (all-rac-α-tocopherol) in 4,495 men and women.
- SELECT Trial: α-tocopheryl acetate at 400 mg in over 35,000 men.
- AREDS Study: 400 IU of vitamin E as part of a combined antioxidant formulation also containing 500 mg vitamin C and zinc.
- Hemorrhagic stroke studies: Two clinical trials found an increased risk of hemorrhagic stroke: one trial included Finnish male smokers who consumed 50 mg/day for an average of 6 years, and the other involved male physicians who consumed 400 IU (180 mg) of synthetic vitamin E every other day for 8 years.
Most vitamin-E-only supplements provide ≥67 mg (100 IU of natural vitamin E) of the nutrient — amounts substantially higher than the RDAs.
6. Safety Considerations and Interactions
Upper Tolerable Intake Level
In supplement form, high doses of vitamin E might increase the risk of bleeding (by reducing the blood's ability to form clots after a cut or injury) and of serious bleeding in the brain (known as hemorrhagic stroke). Because of this risk, the upper limit for adults is 1,000 mg/day for supplements of either natural or synthetic vitamin E, equal to 1,500 IU/day for natural vitamin E supplements and 1,100 IU/day for synthetic vitamin E supplements. Some research suggests that taking vitamin E supplements even below these upper limits might cause harm.
Hemorrhagic Stroke Risk
Vitamin E decreased the risk of ischemic stroke by 10% and raised the risk of hemorrhagic stroke by 22% in a 2010 meta-analysis by Schürks et al. Given that vitamin E showed only a modest reduction in ischemic stroke risk and such a significant increase in the risk of hemorrhagic stroke, it was determined that the dangers of vitamin E supplementation in these subjects outweighed the potential benefits.
Prostate Cancer Risk
The SELECT trial found that high-dose supplementation of vitamin E was linked to an increased risk of prostate cancer. The trial involving over 35,000 male subjects concluded that men taking vitamin E supplements in high doses had a 17% increase in risk of developing prostate cancer.
Anticoagulant and Antiplatelet Interactions
High doses of alpha-tocopherol supplements can cause hemorrhage and interrupt blood coagulation in animals, and in vitro data suggest that high doses inhibit platelet aggregation. Vitamin E supplementation might interact with certain medications, including anticoagulant and antiplatelet medications. Due to its blood-thinning effect, patients on warfarin are warned to be careful taking other supplements such as ginkgo, ginger, and vitamin E, which can potentially increase the risk of bleeding events.
Interaction with Chemotherapy and Radiation
Vitamin E supplementation might also reduce the effectiveness of radiation therapy and chemotherapy by protecting tumor cells from the action of these agents.
Food Sources Are Safe
Research has not found any adverse effects from consuming vitamin E in food. Overt deficiency is very rare, seen only in individuals unable to absorb the vitamin or with inherited abnormalities that prevent the maintenance of normal blood concentrations.
Heart Failure Signal
One analysis reported that vitamin E increases the risk of developing heart failure after myocardial infarction, based on results from the GISSI-Prevenzione trial. This finding warrants consideration in post-MI populations receiving supplement regimens including vitamin E.
7. Body Systems and Health Areas Associated with Vitamin E
- Cardiovascular system: Implicated through antioxidant inhibition of LDL oxidation and platelet aggregation; large RCTs show no benefit for hard endpoints.
- Hepatic system: Studies demonstrated improvement in biochemical profiles with a decline in or normalization of liver enzymes, and histological assessment showed favorable outcomes in lobular inflammation and hepatic steatosis following treatment with vitamin E in NAFLD.
- Neurological system: Vitamin E deficits are associated with impaired motor coordination, cognitive functions, ataxia, and lipid peroxidation.
- Immune system: Vitamin E helps maintain cell membrane integrity and epithelial barriers and by enhancing antibody production, lymphocyte proliferation, and natural killer cell activity.
- Ocular system: Included in the AREDS combination formula shown to slow AMD progression; the eye is particularly susceptible to oxidative stress and disruption of the balance between free radicals and antioxidants.
- Reproductive system: Vitamin E was first discovered as "a hitherto unrecognized dietary factor necessary for reproduction."
- Cell membranes broadly: The main recognized function of α-tocopherol is the antioxidant effect preventing lipid peroxidation of polyunsaturated fatty acids in the cell membrane.
References
Go back